← Back to Clinical Trials
Recruiting NCT05774483

NCT05774483 Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05774483
Status Recruiting
Phase
Sponsor Tata Memorial Hospital
Condition Mouth Neoplasms
Study Type INTERVENTIONAL
Enrollment 508 participants
Start Date 2025-04-16
Primary Completion 2032-04

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Sentinel Node BiopsyLimited Elective Neck Dissection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 508 participants in total. It began in 2025-04-16 with a primary completion date of 2032-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to compare the survival outcomes, morbidity and cost-effectiveness of sentinel node biopsy versus limited elective neck dissection in node-negative early oral cancers. The main questions it aims to answer are: * Survival outcomes * Morbidity outcomes * Cost-effectiveness Participants will either undergo sentinel node biopsy followed by completion neck dissection if sentinel node is reported to be metastatic (SNB) or limited elective neck dissection where level IIb will be cleared only if level IIa is metastatic (limited END). The study will compare the outcomes in the two cohorts.

Eligibility Criteria

Inclusion Criteria: 1. Age \>18 years of age 2. Biopsy-proven invasive squamous cell carcinoma involving the site tongue and buccal mucosa 3. T1 and T2 lesions as per AJCC TNM 8 edition 4. Clinicoradiologically node negative 5. Amenable to per oral excision 6. Treatment naïve 7. No other site of malignancy Exclusion Criteria: 1. Previous surgery in the head and neck region, 2. Upper alveolar or palatal lesions 3. Large heterogeneous leukoplakia or other premalignant lesions 4. Previous malignancy in the head and neck region 5. Patients requiring the free flap reconstruction

Contact & Investigator

Central Contact

Richa Vaish, MS, M.Ch

✉ drvaishricha@gmail.com

📞 02224177000

Principal Investigator

Richa Vaish, MS, M.Ch

PRINCIPAL INVESTIGATOR

Tata Memorial Hospital

Frequently Asked Questions

Who can join the NCT05774483 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Mouth Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05774483 currently recruiting?

Yes, NCT05774483 is actively recruiting participants. Contact the research team at drvaishricha@gmail.com for enrollment information.

Where is the NCT05774483 trial being conducted?

This trial is being conducted at Mumbai, India, Navi Mumbai, India, Varanasi, India.

Who is sponsoring the NCT05774483 clinical trial?

NCT05774483 is sponsored by Tata Memorial Hospital. The principal investigator is Richa Vaish, MS, M.Ch at Tata Memorial Hospital. The trial plans to enroll 508 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology